MTOR and hyperlipidemia: According to previous studies, the replacement of CNIs with mTOR inhibitors also resulted in an insignificant difference in the risk of mortality and graft loss [RR (95% CI), 0.99 (0.96–1.40) and 0.94 (0.75–1.19), respectively], but an increased risk of hyperlipidemia with an RR of 1.76 (95% CI: 1.4–2.2) (Karpe et al., 2017).